Introduction:
The pharmaceutical industry in Israel continues to thrive, with a focus on specialty drugs that cater to specific patient populations. In 2026, the country boasts a strong lineup of premier specialty drug manufacturers who are making a significant impact on the global market. With a production volume of over 1 billion units and exports reaching $5 billion, Israel is establishing itself as a key player in the pharmaceutical arena.
Top 30 Premier Specialty Drug Manufacturers in Israel 2026:
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest pharmaceutical company in Israel, known for its extensive portfolio of specialty drugs. With a market share of 25% in the specialty drug sector, Teva continues to lead the way in innovation and patient care.
2. Perrigo Company plc
Perrigo is a global healthcare company that specializes in self-care products and specialty medications. With a production volume of 500 million units, Perrigo has a strong presence in the Israeli pharmaceutical market.
3. Mylan N.V.
Mylan is a leading specialty pharmaceutical company with a focus on complex generics and biosimilars. With exports exceeding $1 billion, Mylan is a key player in the Israeli pharmaceutical industry.
4. Neopharm Group
Neopharm is a prominent Israeli pharmaceutical company that specializes in oncology and rare diseases. With a market share of 10% in the specialty drug market, Neopharm is known for its innovative treatments and patient-centric approach.
5. Neurim Pharmaceuticals
Neurim is a specialty pharmaceutical company that focuses on developing treatments for sleep disorders and neurological conditions. With a production volume of 100 million units, Neurim continues to make a significant impact on the Israeli pharmaceutical market.
Insights:
Looking ahead, the specialty drug market in Israel is poised for continued growth, driven by an aging population and increasing prevalence of chronic diseases. With a projected market size of $10 billion by 2030, Israeli pharmaceutical companies are well-positioned to capitalize on emerging trends and expand their global presence. Additionally, collaborations with international partners and investments in research and development will be key strategies for maintaining competitiveness in the evolving pharmaceutical landscape.
Related Analysis: View Previous Industry Report
